Internal Medicine Alert – September 30, 2003

September 30, 2003

• The Nose Knows . . .

  Patients with unexplained chronic fatigue and bodily pain are more likely to have rhinosinusitis symptoms than are people in the general population.

  Read more

• Endoscopic Therapy in Patients Receiving Omeprazole for Bleeding Ulcers with Nonbleeding Visible Vessels or Adherent Clots

  There are arguments about the optimal treatment for ulcers with nonbleeding visible vessels and adherent clots. This study showed that the combination of endoscopic hemostasis with IV proton pump inhibitor therapy is superior to PPI alone in management of such patients.

  Read more

• Life Can be Less Risky!

  Eighty-seven percent or more of patients with fatal or nonfatal myocardial infarction have major risk factors prior to the event.

  Read more

• Azithromycin as Single-Drug Therapy for Community-Acquired Pneumonia

  Azithromycin is an effective, single-drug therapy for mild-to-moderate community-acquired pneumonia.

  Read more

• Pharmacology Update: Vardenafil Tablets — Levitra

  Vardenafil has been approved for the treatment of erectile dysfunction in men. The drug is the second oral type 5 phosphodiestase (PDE5) inhibitor approved for this indication along with sildenafil (Viagra).

  Read more

• Clinical Briefs in Diabetes

  Insulin 70/30 Mix Plus Metformin vs Triple Oral Therapy in Type 2 Diabetes; ARB and ACE-I in Diabetic Nephropathy; Low-Glycemic Index Diets and Diabetes

  Read more